



Share Purchase Plan Finalisation

Highlights

- *SPP applications received for approximately A\$ 1.88M, representing a 94% uptake.*
- *Total of A\$ 8M raised via a A\$ 6M Private Placement and a A\$ 2M SPP (fully underwritten).*
- *Funds raised will be put towards accelerating the final stages of preparation to launch a portfolio of IDT's own generic drug products into the US and potentially other markets.*
- *Holding statements expected to be dispatched today.*

23 December 2015, Melbourne: IDT Australia Limited (IDT.AX) advises that the Company has received and will accept AUD 1,884,500 in eligible applications under the Share Purchase Plan (SPP) announced on 19 November 2015, which closed on 15 December 2015. The SPP shares will be allotted at \$A0.35 per share, the same price as applied to the recent \$A 6M private placement to institutional and sophisticated investors.

After the necessary scaling back, IDT confirms it will accept all eligible SPP applications and will issue 5,384,430 fully paid ordinary shares which will rank pari-passu with existing shares. The AUD 115,500 shortfall (being 330,000 shares) (Shortfall Shares) in the AUD 2M total to be raised under the SPP has been placed to sophisticated and institutional investors pursuant to the Company's underwriting agreement with Wilson HTM Corporate Finance Limited, under the Company's ASX Listing Rule 7.1 entitlement. Dispatch of holding statements is expected to occur today.

Accompanying this announcement is the Company's Appendix 3B for all of the Shares issued under the SPP and the Shortfall Shares, and a cleansing notice for the Shortfall Shares.

The Company is very pleased with the level of interest in the SPP, which represents a 94% uptake. Funds raised will be used to accelerate the commercialisation of the 23 previously marketed US generic drug products the Company acquired late last year, as well as fund capacity expansion for IDT's in-house proprietary drug development program.

This is an exciting time for the Company as we enter the final stages of preparation to launch a portfolio of IDT's own generic drug products into the US and potentially other markets. These monies raised will allow IDT to accelerate this process. IDT Australia Limited sincerely thanks shareholders for their ongoing support.

Dr David Sparling / Ms Joanna Johnson
Joint Company Secretary